Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs - 2Explora Journeys becomes latest cruise line to be impacted by Middle East war
- 3Supportive Tips On Home loans For First-Time Home Purchasers
- 4Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- 5A definitive Manual for the 5 Off-road Bicycles Available
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- The Appearance of Experience: Embracing the Reduced Portage Horse
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- A Manual for Extravagant Vehicles Available in 2024
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- Artemis II astronauts arrive in Florida to prepare for launch to the moon
- Seven deaths possibly linked to malfunctioning glucose monitors
- The Best Internet based Courses for Expertise Improvement
- Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
